Two case reports involving one 46-year-old adult with relapsed B-ALL harboring a mixed-lineage leukemia fusion gene and two adult male patients with T-ALL carrying the SET-NUP214 fusion present promising data on a safe use of chidamide with the BCL2 protein inhibitor venetoclax and azacytidine or post-hematopoietic stem cell transplantation [48, 49]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.